Eurosurveillance · 2024 · 63 citations · 14 references
Veterinary MedicineImmunologyInfectious DiseasesImmunizationVaccine ImmunologyVaccinologyAdult ImmunizationClinical Vaccine TrialsVaccinationVaccine DevelopmentVaccine EffectivenessVaccine EfficacyAge-specific Vaccine EffectivenessEfficacy Against InfectionOverall Vaccine EffectivenessPopulation-based Vaccine EffectivenessPrior Infection HistoryProspective Cohort DataSars-cov-2 InfectionVariant-specific Vaccine Effectiveness
We estimated vaccine effectiveness (VE) of SARS-CoV-2 Omicron XBB.1.5 vaccination against self-reported infection between 9 October 2023 and 9 January 2024 in 23,895 XBB.1.5 vaccine-eligible adults who had previously received at least one booster. VE was 41% (95% CI: 23-55) in 18-59-year-olds and 50% (95% CI: 44-56) in 60-85-year-olds. Sequencing data suggest lower protection against the BA.2.86 (including JN.1) variant from recent prior infection (OR = 2.8; 95% CI:1.2-6.5) and, not statistically significant, from XBB.1.5 vaccination (OR = 1.5; 95% CI:0.8-2.6).
14
Antigenicity and receptor affinity of SARS-CoV-2 BA.2.86 spike
Qian Wang, Yicheng Guo, Liyuan Liu et al. · Nature · 2023 · 206 citations · Full text
Ruth Link‐Gelles, Allison Avrich Ciesla, Katherine E. Fleming-Dutra et al. · MMWR Morbidity and Mortality Weekly Report · 2022 · 188 citations · Full text
Ruth Link‐Gelles, Allison Avrich Ciesla, Josephine Mak et al. · MMWR Morbidity and Mortality Weekly Report · 2024 · 167 citations · Full text
Veterinary Medicine, Infectious Diseases, Preventive Medicine +17
Covid-19: WHO adds JN.1 as new variant of interest
Mun-Keat Looi · BMJ · 2023 · 84 citations · Full text
Veterinary Medicine, Infectious Diseases, Molecular Genetics +4